Atea director granted options, RSUs and shares

Atea Pharmaceuticals director Polly A. Murphy reported equity compensation activity and an RSU vesting-related share delivery.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Atea Pharmaceuticals director Polly A. Murphy reported equity compensation activity and an RSU vesting-related share delivery. On June 18, 2026, RSUs covering 29,600 shares of common stock were exercised into common stock, leaving her with 121,745 common shares directly held.

On the same date, she received a stock option grant for 37,700 shares of common stock at an exercise price of $4.36 per share, vesting in twelve substantially equal monthly installments through June 18, 2027, and expiring on June 17, 2036. She was also granted 26,700 restricted stock units, each representing one share of common stock, vesting in a single installment on the earlier of the next annual stockholder meeting after June 18, 2026 or June 18, 2027, subject to continued service.

Insider Trade Summary

29,600 shares exercised/converted

Exercise 4 txns

Insider Murphy Polly A.

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	29,600	$0.00	$0.00
Grant/Award	Restricted Stock Units	26,700	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	37,700	$0.00	$0.00
Exercise	Common Stock	29,600	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 26,700 contracts (Direct); Stock Option (Right to Buy) — 37,700 contracts (Direct); Common Stock — 121,745 shares (Direct)

Footnotes (4)

F1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2. The RSUs vested in full on June 18, 2026.
F3. The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after June 18, 2026 or (ii) June 18, 2027, in each case, subject to the Reporting Person's continued service through the applicable vesting date.
F4. The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 18, 2026, such that the option shall be fully vested on June 18, 2027, subject to the Reporting Person's continued service through each such vesting date.

Key Figures

RSUs converted to common: 29,600 shares Common shares held after: 121,745 shares New stock option grant: 37,700 options +4 more

7 metrics

RSUs converted to common 29,600 shares Restricted stock units exercised into common stock on June 18, 2026

Common shares held after 121,745 shares Direct holdings after RSU exercise on June 18, 2026

New stock option grant 37,700 options Right to buy common stock granted on June 18, 2026

Option exercise price $4.36 per share Conversion or exercise price for 37,700 stock options

Option expiration June 17, 2036 Expiration date for 37,700 stock options

New RSU grant 26,700 RSUs Restricted stock units granted on June 18, 2026

Option vesting period 12 monthly installments Vests after June 18, 2026, fully vested by June 18, 2027

Key Terms

Restricted Stock Units, Stock Option (Right to Buy), exercise or conversion of derivative security, vesting

4 terms

Restricted Stock Units financial

"Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy) covering 37,700 shares of Common Stock was granted on June 18, 2026."

exercise or conversion of derivative security financial

"Transaction code M is described as Exercise or conversion of derivative security."

vesting financial

"The option vests and becomes exercisable in twelve substantially equal monthly installments following June 18, 2026."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Polly A. Murphy report at Atea Pharmaceuticals (AVIR)?

Polly A. Murphy reported an RSU exercise into 29,600 Atea Pharmaceuticals common shares and new grants of 37,700 stock options and 26,700 restricted stock units, all dated June 18, 2026, as part of her director equity compensation.

How many Atea Pharmaceuticals shares does Polly A. Murphy hold after these Form 4 transactions?

After the June 18, 2026 RSU exercise, Polly A. Murphy directly holds 121,745 shares of Atea Pharmaceuticals common stock. This figure reflects her position following delivery of 29,600 shares from vested restricted stock units reported in the Form 4.

What are the key terms of Polly A. Murphy’s new stock option grant at Atea Pharmaceuticals?

Murphy received options for 37,700 Atea Pharmaceuticals shares at an exercise price of $4.36 per share. The options vest in twelve substantially equal monthly installments after June 18, 2026 and are scheduled to be fully vested by June 18, 2027, subject to continued service.

How do Polly A. Murphy’s new restricted stock units at Atea Pharmaceuticals vest?

Murphy received 26,700 restricted stock units, each representing one Atea Pharmaceuticals common share. These RSUs vest in a single installment on the earlier of the next annual stockholder meeting after June 18, 2026 or June 18, 2027, contingent on her continued service.

Were any Atea Pharmaceuticals shares sold in Polly A. Murphy’s latest Form 4 filing?

No sales were reported. The filing shows an RSU-to-common-stock conversion of 29,600 shares and new grants of stock options and restricted stock units, all classified as acquisitions rather than open-market purchases or sales of Atea Pharmaceuticals shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/23/2026 - 05:00 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Murphy Polly A.

(Last)

(First)

(Middle)

225 FRANKLIN STREET

SUITE 2100

(Street)

BOSTON

MASSACHUSETTS

02110

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Atea Pharmaceuticals, Inc. [ AVIR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/18/2026		M		29,600	A	$0⁽¹⁾	121,745	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	06/18/2026		M			29,600	⁽²⁾	⁽²⁾	Common Stock	29,600	$0	0	D
Restricted Stock Units	⁽¹⁾	06/18/2026		A		26,700		⁽³⁾	⁽³⁾	Common Stock	26,700	$0	26,700	D
Stock Option (Right to Buy)	$4.36	06/18/2026		A		37,700		⁽⁴⁾	06/17/2036	Common Stock	37,700	$0	37,700	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

2. The RSUs vested in full on June 18, 2026.

3. The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after June 18, 2026 or (ii) June 18, 2027, in each case, subject to the Reporting Person's continued service through the applicable vesting date.

4. The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 18, 2026, such that the option shall be fully vested on June 18, 2027, subject to the Reporting Person's continued service through each such vesting date.

	/s/ Andrea Corcoran, as Attorney-in-Fact for Polly A. Murphy	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR